Abstract
Guidelines already recommend non-vitamin K oral anticoagulants (NOAC) over vitamin-K antagonists (VKA) for stroke prevention in patients with atrial fibrillation. However, recommendations are lacking with respect to which NOAC to use. At the moment, NOACs may employ two different molecular mechanisms: Factor Ha inhibition (dabigatran) and factor Xa inhibition (apixaban, edoxaban, rivaroxaban). The focus of this review is to compare and contrast potential differences between factor IIa- and factor Xa inhibition with respect to risk of myocardial infarction and to detail underlying mechanisms. (C) 2018 Elsevier Inc. All rights reserved.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
ISSN: | 0163-7258 |
Sprache: | Englisch |
Dokumenten ID: | 80352 |
Datum der Veröffentlichung auf Open Access LMU: | 15. Dez. 2021, 14:53 |
Letzte Änderungen: | 15. Dez. 2021, 14:53 |